References
- Bernard Bonnetblanc J-M. Dermatomyositis and malignancy. J Invest Dermatol 1993; 100: 128S–132S
- Bohan A, Peter J B. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 345–7; 403–7
- Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162–8
- Derancourt C, Humbert P H, Agache P. Immunoglobulines polyvalentes intraveineuses: utilisation en dermatologie. Ann Dermatol Venereol 1992; 119: 487–8
- Lang B A, Laxer R M, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169–72
- Dalakas M C, Illa I, Dambrosia J M, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000
- Immunoglobuline per uso endovenoso. Med Lett 1993; XXII: 14–16
- Meroni P L. Immunodeficienze. Diagnosi e terapia medica pratica, C Zanussi. UTET, Torino 1991; 335–45
- NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990; 264: 3189–93
- Collet E, Dalac S, Maerens B, et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 1994; 130: 231–4
- Dwyer J M. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107–16
- Kaveri S V, Dietrich G, Hurez V, et al. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991; 86: 192–8
- Goodman J W. The immune response. Basic and clinical immunology7th edn., D P Stites, I A Terr. Lange Medical Publications, London 1991; 34–44